이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Thyrocare Technologies 관리

관리 기준 확인 0/4

Thyrocare Technologies' CEO는 Rahul Guha, May2022 에 임명되었습니다 의 임기는 2.08 년입니다. 는 ₹ 33.49M 가치에 해당하는 회사 주식의 0.099% 직접 소유합니다. 33.49M. 경영진과 이사회의 평균 재임 기간은 각각 1.5 년과 2.8 년입니다.

주요 정보

Rahul Guha

최고 경영자

₹31.8m

총 보상

CEO 급여 비율	n/a
CEO 임기	2.2yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	1.5yrs
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Recent updates

CEO

Rahul Guha (46 yo)

2.2yrs

테뉴어

₹31,801,079

보상

Mr. Rahul Franklin Guha is Managing Director, Chief Executive Officer and Director of Thyrocare Technologies Limited from May 04, 2022 and also serves as its Chairman since April 07, 2023. He joined the Th...

리더십 팀

이름	위치	테뉴어	보상	소유권
Rahul Guha	MD, CEO & Chairman	2.2yrs	₹31.80m	0.099% ₹ 34.1m
K. KallathiKumar	Chief Operating Officer	no data	₹9.89m	0.0030% ₹ 1.0m
Ramjee Dorai	Company Secretary & Compliance Officer	9.8yrs	₹3.09m	0.040% ₹ 13.7m
Aditya Shinde	Vice President	no data	₹5.33m	0.0020% ₹ 687.5k
Alok Jagnani	Chief Financial Officer	less than a year	데이터 없음	0% ₹ 0
Pratik Hire	Head of Strategy & Investor Relations	no data	데이터 없음	데이터 없음
Nitin Chugh	Chief Commercial Officer	less than a year	데이터 없음	데이터 없음

1.5yrs

평균 재임 기간

46yo

평균 연령

경험이 풍부한 관리: 539871 의 관리팀은 경험 (평균 재직 기간 1.5 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Rahul Guha	MD, CEO & Chairman	2.2yrs	₹31.80m	0.099% ₹ 34.1m
Gopal Krishna Hegde	Independent Non-Executive Director	9.9yrs	₹160.00k	데이터 없음
Neetin Desai	Independent Non-Executive Director	9.8yrs	₹50.00k	데이터 없음
Indumati Gopinathan	Non-Executive Independent Director	6.9yrs	₹70.00k	데이터 없음
Dharmil Sheth	Non-Executive & Non-Independent Director	2.8yrs	데이터 없음	데이터 없음
Hardik Dedhia	Non Executive Director	2.8yrs	데이터 없음	데이터 없음
Dhaval Shah	Non Executive Director	2.8yrs	데이터 없음	데이터 없음
Prapti Gilada	Independent Director	less than a year	데이터 없음	데이터 없음
Harshil Vora	Non-Executive Independent Director	less than a year	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

36yo

평균 연령

경험이 풍부한 이사회: 539871 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Thyrocare Technologies 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

High number of new directors

MD, CEO & Chairman recently bought ₹4.3m worth of stock

Thyrocare Technologies Limited Appoints Alok Kumar Jagnani as Chief Financial Officer

High number of new directors

Thyrocare Technologies Limited Accepts Resignation of Sachin Salvi as Chief Financial Officer

Thyrocare Technologies Limited Announces Resignation of Vishwas Kulkarni as an Independent Director

Recent updates

Now 23% overvalued after recent price rise

Thyrocare Technologies Limited Proposes Final Dividend for the Financial Year 2023-24

Thyrocare Technologies Limited to Report Q4, 2024 Results on May 14, 2024

Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Think Health Diagnostic Private Limited.

High number of new directors

Third quarter 2024 earnings released: EPS: ₹2.78 (vs ₹1.89 in 3Q 2023)

Thyrocare Technologies Limited to Report Q3, 2024 Results on Feb 01, 2024

Price target increased by 7.3% to ₹695

Second quarter 2024 earnings released: EPS: ₹3.84 (vs ₹3.80 in 2Q 2023)

Thyrocare Technologies Limited to Report Q2, 2024 Results on Oct 31, 2023

MD, CEO & Chairman recently bought ₹4.3m worth of stock

Thyrocare Technologies Limited Appoints Alok Kumar Jagnani as Chief Financial Officer

Price target decreased by 18% to ₹643

High number of new directors

Thyrocare Technologies Limited to Report Q1, 2024 Results on Aug 01, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited Accepts Resignation of Sachin Salvi as Chief Financial Officer

Consensus EPS estimates fall by 27%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q4, 2023 Results on May 23, 2023

Thyrocare Technologies Limited Announces Resignation of Vishwas Kulkarni as an Independent Director

Upcoming dividend of ₹18.00 per share at 3.1% yield

MD, CEO & Director recently bought ₹10m worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q3, 2023 Results on Feb 03, 2023

Consensus EPS estimates fall by 19%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited (BSE:539871) agreed to acquire 51% stake in Pulse Hitech Health Services (Ghatkopar) LLP for INR 25.5 million.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q2, 2023 Results on Nov 11, 2022

MD, CEO & Director recently bought ₹16m worth of stock

Consensus EPS estimates fall by 12%

Thyrocare Technologies Limited Announces Payment of Interim Dividend for the Financial Year 2021-2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited, Annual General Meeting, Aug 03, 2022

Price target decreased to ₹1,073

Consensus forecasts updated

Thyrocare Technologies Limited Joins Rahul Guha as Managing Director

Thyrocare Technologies Limited Declares Interim Dividend for the Financial Year 2021-22

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q4, 2022 Results on Apr 29, 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Thyrocare Technologies Limited Announces Appointment of Rahul Guha as Managing Director

Thyrocare Technologies Limited Appoints Sachin Salvi as Chief Financial Officer

First quarter 2022 earnings released: EPS ₹10.51 (vs ₹0.04 in 1Q 2021)

Consensus forecasts updated

First quarter 2022 earnings released: EPS ₹10.51 (vs ₹0.04 in 1Q 2021)

Price target increased to ₹1,233

Docon Technologies Private Limited entered into a share purchase agreement to acquire 66.11% stake in Thyrocare Technologies Limited (BSE:539871) from a group of shareholders for INR 45.5 billion.

Pharmeasy Looks to Acquire a Stake in Thyrocare

Investor sentiment improved over the past week

Upcoming dividend of ₹15.00 per share

Full year 2021 earnings released: EPS ₹21.41 (vs ₹16.74 in FY 2020)

Full year 2021 earnings released: EPS ₹21.41 (vs ₹16.74 in FY 2020)

Investor sentiment improved over the past week

New 90-day low: ₹868

Analysts lower EPS estimates to ₹20.97

Third quarter 2021 earnings released: EPS ₹6.13 (vs ₹5.21 in 3Q 2020)

Revenue and earnings miss expectations

New 90-day low: ₹903

Thyrocare Technologies Limited to Report Q3, 2021 Results on Jan 30, 2021

Chairman & MD recently bought ₹6.3m worth of stock

Upcoming Dividend of ₹10.00 Per Share

Analysts increase revenue estimates to ₹5.34b

First half earnings released

Second-quarter earnings released: Revenue misses expectations

New 90-day high: ₹1,136

Price target raised to ₹775

Chairman recently bought ₹20m worth of stock